These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27665778)

  • 21. Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate.
    Moffit JS; Koza-Taylor PH; Holland RD; Thibodeau MS; Beger RD; Lawton MP; Manautou JE
    Toxicol Appl Pharmacol; 2007 Jul; 222(2):169-79. PubMed ID: 17585979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity.
    Liu A; Krausz KW; Fang ZZ; Brocker C; Qu A; Gonzalez FJ
    Arch Toxicol; 2014 Apr; 88(4):983-96. PubMed ID: 24385052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation.
    McCarthy TC; Pollak PT; Hanniman EA; Sinal CJ
    J Pharmacol Exp Ther; 2004 Dec; 311(3):864-73. PubMed ID: 15265979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.
    Oshida K; Vasani N; Thomas RS; Applegate D; Rosen M; Abbott B; Lau C; Guo G; Aleksunes LM; Klaassen C; Corton JC
    PLoS One; 2015; 10(2):e0112655. PubMed ID: 25689681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.
    Yamazaki K; Kuromitsu J; Tanaka I
    Biochem Biophys Res Commun; 2002 Jan; 290(3):1114-22. PubMed ID: 11798191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
    Guo L; Fang H; Collins J; Fan XH; Dial S; Wong A; Mehta K; Blann E; Shi L; Tong W; Dragan YP
    BMC Bioinformatics; 2006 Sep; 7 Suppl 2(Suppl 2):S18. PubMed ID: 17118139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma mannose-binding lectin is stimulated by PPARα in humans.
    Rakhshandehroo M; Stienstra R; de Wit NJ; Bragt MC; Haluzik M; Mensink RP; Müller M; Kersten S
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E595-602. PubMed ID: 22215653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate causes upregulation of organic cation transporter 2 in liver and small intestine of rats.
    Ringseis R; Pösel S; Hirche F; Eder K
    Pharmacol Res; 2007 Aug; 56(2):175-83. PubMed ID: 17644405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver.
    Anderson SP; Dunn C; Laughter A; Yoon L; Swanson C; Stulnig TM; Steffensen KR; Chandraratna RA; Gustafsson JA; Corton JC
    Mol Pharmacol; 2004 Dec; 66(6):1440-52. PubMed ID: 15371561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxisome Proliferator-Activated Receptor α Activation Suppresses Cytochrome P450 Induction Potential in Mice Treated with Gemfibrozil.
    Shi C; Min L; Yang J; Dai M; Song D; Hua H; Xu G; Gonzalez FJ; Liu A
    Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):169-174. PubMed ID: 28374976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Agonist-induced down-regulation of hepatic glucocorticoid receptor via peroxisome proliferator-activated receptor in SD rats].
    Chen X; Li M; Sun WP; Bi Y; Cai MY; Liang H; Yu QQ; He XY; Weng JP
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(46):3276-9. PubMed ID: 20193367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feeding oxidized fat during pregnancy up-regulates expression of PPARalpha-responsive genes in the liver of rat fetuses.
    Ringseis R; Gutgesell A; Dathe C; Brandsch C; Eder K
    Lipids Health Dis; 2007 Mar; 6():6. PubMed ID: 17352811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender-related difference in the toxicity of ultraviolet absorber 2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole in rats.
    Hirata-Koizumi M; Matsuyama T; Imai T; Hirose A; Kamata E; Ema M
    Drug Chem Toxicol; 2008; 31(3):383-98. PubMed ID: 18622872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms.
    Mezei O; Li Y; Mullen E; Ross-Viola JS; Shay NF
    Physiol Genomics; 2006 Jun; 26(1):8-14. PubMed ID: 16507786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones.
    Jalouli M; Carlsson L; Améen C; Lindén D; Ljungberg A; Michalik L; Edén S; Wahli W; Oscarsson J
    Endocrinology; 2003 Jan; 144(1):101-9. PubMed ID: 12488335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats.
    Zhang Y; Jiang Z; Su Y; Chen M; Li F; Liu L; Sun L; Wang Y; Zhang S; Zhang L
    J Appl Toxicol; 2013 Aug; 33(8):807-19. PubMed ID: 22431067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of PPARalpha-dependent and PPARalpha-independent transcript regulation following fenofibrate treatment of human endothelial cells.
    Araki H; Tamada Y; Imoto S; Dunmore B; Sanders D; Humphrey S; Nagasaki M; Doi A; Nakanishi Y; Yasuda K; Tomiyasu Y; Tashiro K; Print C; Charnock-Jones DS; Kuhara S; Miyano S
    Angiogenesis; 2009; 12(3):221-9. PubMed ID: 19357976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric mice with hepatocyte-humanized liver as an appropriate model to study human peroxisome proliferator-activated receptor-α.
    Tateno C; Yamamoto T; Utoh R; Yamasaki C; Ishida Y; Myoken Y; Oofusa K; Okada M; Tsutsui N; Yoshizato K
    Toxicol Pathol; 2015 Feb; 43(2):233-48. PubMed ID: 25107573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.